At 270 million prescriptions per year, anti-depressants are the most consumed class of therapeutics in the US. However, sales revenue does not match prescription numbers.
The US Antidepressant market peaked at $12 billion in 2008, lost $2.6 billion due to expired patents during the following years and currently stands at $9.4 billion. Over the past five years, the market has been declining, on average, by (-4%) per year.
Branded pharmaceutical companies are increasingly pulling out the antidepressant market, despite widespread use of the medication, as patent expiry and new drug development failures make it unprofitable to remain in the market.
However, the market still holds promise for that innovative player that would manage to exact value out of the current dissatisfaction of treatment outcome experienced by both patients and physicians alike.
Pharma Reports are short insightful quality documents targeted at product, brand, portfolio and marketing managers. We know you are busy, we know that you have access to all available data and that your time comes at a premium. We offer helicopter view insights and are always available to discuss your specific information needs.
Authored by: Pharma Reports
Published: February 2013
Number of Pages: #5
Table of Contents
1. US Pharma Market
2. US Anti-Depressant Market
3. Top Five US Anti-Depressant Brands
4. Impact of Generic Competition on US Antidepressant Market
5. US Anti-Depressant Market Forecast
List of Table & Figures
1. US GDP & Population in Perspective
2. US Ethical Pharmaceutical Market Revenue and Growth Trend (2007 – 2012)
3. US Anti-Depressant Market Revenue and Growth Trend (2007 – 2012)
4. Top Five US Anti-Depressant Brands Revenue and Growth Trend (2007 – 2012)
5. US Anti-Depressant Market - Leading Brands Market Shares (2012)
6. US Anti-depressant Market Forecast (2013 – 2018)
Companies Mentioned
1. Eli Lilly
2. Forest Laboratories
3. GSK
4. Mylan
5. Pfizer
6. Ranbaxy
7. Teva
8. Watson